Philips Machines linked to Cancer and Death

Continuous Positive Airway Pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) machines are commonly used to treat sleep apnea.

Numerous CPAP and BiPAP sleep apnea ventilators were voluntarily recalled by Philips Respironics on June 21, 2021. It was discovered that the recalled machines released faulty sound-absorbing foam. Toxic gasses or particles found in this foam can enter the user’s airway directly. This may result in deaths or other severe health consequences, including a variety of cancers and/or pulmonary/lung injuries.

Philips has recalled the following machines due to the toxic foam that was used in the machines:

  • A-Series BiPAP A30
  • A-Series BiPAP Hybrid A30
  • Aeris
  • C-Series ASV
  • C-Series S/T and AVAPS
  • Dorma 400, 500, Auto
  • DreamStation ASV, Go, ST, Auto, and AVAPS
  • E30
  • Garbin Plus
  • LifeVent
  • OmniLab Advanced Plus
  • REMstar SE Auto
  • SystemOne ASV4, Q-Series, 50 series, and 60 series
  • Trilogy 100
  • Trilogy 200

Injuries Associated with Philips CPAP, BiPAP, and Ventilators


  • Blood Cancer
  • Bone marrow Cancer
  • Esophageal Cancer
  • Hematopoietic Cancer
  • Laryngeal Cancer
  • Leukemia Cancer
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Kidney Cancer
  • Multiple myeloma Cancer
  • Nasal Cancer
  • Non-Hodgkin’s lymphoma
  • Papillary/Thyroid Cancer
  • Oral/Soft Palate Cancer
  • Sinus Cancer
  • Throat/Tonsil Cancer

Pulmonary & Lung Injuries

  • Lung damage
  • Pleural effusion
  • Pneumonia
  • Pulmonary fibrosis
  • Respiratory failure (ARDS)
  • Reactive airway disease (RAD)

What should I do next?

If you or a loved one has been diagnosed with cancer or a serious lung disease after exposure to Philips CPAP or BiPAP, Wagstaff & Cartmell may be able to help. Our products liability lawyers can examine your case and help you understand your rights. There are time limits which may affect the filing of your claim. Please contact us by using the online form or by calling our office at 816-701-1100 so that we may better evaluate your case.

See All News & Perspectives

Go To All News